MAPT and Alzheimer disease: The main goals of this study were to test whether: (i) N-terminal tau cleavage occurred in ICV-STZ preclinical model of sAD; (ii) 12A12mAb delivery exerted an in vivo beneficial action on the cognitive and neurochemical and neuropathological hallmarks associated with animals’ AD phenotype.